WHO’s drug recommendations expose inequities in global COVID-19 treatment access and patent monopolies
Original framing: “WHO recommends two new drugs to treat COVID-19” — WHO News
The current drug access crisis mirrors the HIV/AIDS epidemic of the 1990s, where patent protections delayed generic production of life-saving antiretrovirals in Africa for over a decade. Similarly, the 2009 H1N1 pandemic saw pharmaceutical companies hoard Tamiflu, demonstrating how market mechanisms prioritize profit over public health. The WHO’s recommendation of baricitinib without addressing these precedents ignores how intellectual property laws—enforced by bodies like the WTO—have repeatedly enabled corporate control over global health crises. This historical amnesia allows the same structural failures to recur under new names.
The WHO’s drug recommendations expose a fundamental tension in global health governance: the conflict between corporate profit incentives and the ethical imperative of equitable access.
While the framing presents baricitinib as a neutral medical advancement, its omission of historical parallels (HIV/AIDS), cross-cultural alternatives (Cuba’s vaccines), and marginalized voices (Global South healthcare workers) reveals a system designed to prioritize patent holders over public health. The trickster lens cuts through this illusion by exposing the absurdity of celebrating 'new drugs' while the same structures that delayed HIV treatments now repeat themselves. Solutions require dismantling intellectual property barriers, integrating Indigenous and community-led health models, and holding pharmaceutical corporations accountable through reparative wealth redistribution. The crisis is not a lack of scientific solutions but a failure of political will to treat COVID-19 as a collective, rather than a market-driven, emergency.